Skip to content
DataLookout
Menu

NCT07915258

Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Head and Neck Squamous Cell Carcinoma With Suboptimal Response to Induction Immunochemotherapy

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Objective Response Rate (ORR)
Timeframe: From baseline to preoperative tumor assessment after two treatment cycles (approximately 6-10 weeks after the first dose)

Secondary (9)

Pathological Complete Response Rate (pCR)
Major Pathological Response Rate (MPR)
R0 Resection Rate
Organ Preservation Rate
Incidence of Adverse Events (AEs)
Show 4 moreShow less
Event-Free Survival (EFS) Rate at 1 and 2 Years
Disease-Free Survival (DFS) Rate at 1 and 2 Years
Overall Survival (OS) Rate at 1 and 2 Years
Clinicopathological Downstaging Rate

Arms and interventions

Adaptive Neoadjuvant TherapyExperimental

Patients with locally advanced, resectable head and neck squamous cell carcinoma who have achieved stable disease or progressive disease following induction immunochemotherapy will receive becotatug vedotin (MRG003) at 2.0 mg/kg and pucotenlimab (HX008) at 200 mg intravenously every three weeks for two cycles, followed by curative-intent surgery and standard postoperative treatment as clinically indicated.

Drugs: Becotatug Vedotin (MRG003), Pucotenlimab

Sites

4 sites in 1 country